- Home
- BIRD vs IOBT Comparison
BIRD vs IOBT Comparison
Compare BIRD & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$3.15
HOLD
Current Price
$0.34
Company Overview
Basic Information| Metric | BIRD | IOBT |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 26.6M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BIRD | IOBT |
|---|---|---|
| Price | $3.15 | $0.34 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | ★ $11.00 | $2.25 |
| AVG Volume (30 Days) | 60.9K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $189,757,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $0.21 |
| 52 Week High | $12.84 | $2.79 |
Technical Indicators
Market Signals| Indicator | BIRD | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 25.91 | 45.34 |
| Support Level | $2.96 | $0.35 |
| Resistance Level | $3.21 | $0.39 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 16.06 | 75.88 |
Price Performance
Historical Comparison BIRD
IOBT
About BIRD Allbirds Inc.
Allbirds Inc is a lifestyle brand that innovates with naturally derived materials to make footwear and apparel products in a better way, while treading lighter on the planet. Its primary source of revenue is from sales of shoes and apparel products. The majority of the revenue is derived from United States.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.